Literature DB >> 33547217

In Search of the Optimal Target for Phosphate Control: Episode 1.

Ron Wald1,2,3, Michael W Walsh4,5,6,7.   

Abstract

Entities:  

Keywords:  phosphate binders; randomized controlled trials; vascular calcification

Mesh：

Substances：

Year:  2021        PMID： 33547217      PMCID： PMC7920181          DOI： 10.1681/ASN.2021010027

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  11 in total

1.  KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).

Authors: 
Journal:  Kidney Int Suppl (2011)       Date:  2017-06-21

2.  Two phosphAte taRGets in End-stage renal disease Trial (TARGET): A Randomized Controlled Trial.

Authors:  Ron Wald; Christian G Rabbat; Louis Girard; Amit X Garg; Karthik Tennankore; Jessica Tyrwhitt; Andrew Smyth; Andrea Rathe-Skafel; Peggy Gao; Andrea Mazzetti; Jackie Bosch; Andrew T Yan; Patrick Parfrey; Braden J Manns; Michael Walsh
Journal:  Clin J Am Soc Nephrol       Date:  2017-05-26       Impact factor: 8.237

3.  Phosphate regulation of vascular smooth muscle cell calcification.

Authors:  S Jono; M D McKee; C E Murry; A Shioi; Y Nishizawa; K Mori; H Morii; C M Giachelli
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

Review 4.  Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis.

Authors:  Suetonia C Palmer; Andrew Hayen; Petra Macaskill; Fabio Pellegrini; Jonathan C Craig; Grahame J Elder; Giovanni F M Strippoli
Journal:  JAMA       Date:  2011-03-16       Impact factor: 56.272

5.  Pill burden, adherence, hyperphosphatemia, and quality of life in maintenance dialysis patients.

Authors:  Yi-Wen Chiu; Isaac Teitelbaum; Madhukar Misra; Essel Marie de Leon; Tochi Adzize; Rajnish Mehrotra
Journal:  Clin J Am Soc Nephrol       Date:  2009-05-07       Impact factor: 8.237

6.  Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients.

Authors:  Glenn M Chertow; Steven K Burke; Paolo Raggi
Journal:  Kidney Int       Date:  2002-07       Impact factor: 10.612

7.  Phosphate-Binder Use in US Dialysis Patients: Prevalence, Costs, Evidence, and Policies.

Authors:  Wendy L St Peter; Lori D Wazny; Eric D Weinhandl
Journal:  Am J Kidney Dis       Date:  2017-11-28       Impact factor: 8.860

8.  Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.

Authors:  Yoshitaka Isaka; Takayuki Hamano; Hideki Fujii; Yoshihiro Tsujimoto; Fumihiko Koiwa; Yusuke Sakaguchi; Ryoichi Tanaka; Noriyuki Tomiyama; Fuminari Tatsugami; Satoshi Teramukai
Journal:  J Am Soc Nephrol       Date:  2021-02-05       Impact factor: 10.121

9.  Design and Rationale of HiLo: A Pragmatic, Randomized Trial of Phosphate Management for Patients Receiving Maintenance Hemodialysis.

Authors:  Daniel L Edmonston; Tamara Isakova; Laura M Dember; Steven Brunelli; Amy Young; Rebecca Brosch; Srinivasan Beddhu; Hrishikesh Chakraborty; Myles Wolf
Journal:  Am J Kidney Dis       Date:  2020-12-03       Impact factor: 8.860

10.  A randomized controlled trial of different serum phosphate ranges in subjects on hemodialysis.

Authors:  Ramya Bhargava; Philip A Kalra; Mark Hann; Paul Brenchley; Helen Hurst; Alastair J Hutchison
Journal:  BMC Nephrol       Date:  2019-02-04       Impact factor: 2.388
View more
  1 in total

1.  A real-world analysis of the influence of age on maintenance hemodialysis patients: managing serum phosphorus with sucroferric oxyhydroxide as part of routine clinical care.

Authors:  Connie M Rhee; Meijiao Zhou; Rachael Woznick; Claudy Mullon; Michael S Anger; Linda H Ficociello
Journal:  Int Urol Nephrol       Date:  2022-08-11       Impact factor: 2.266
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.